The Life Sciences team guided Repertoire Immune Medicines on entering a strategic collaboration with Eli Lilly and Company (“Lilly”) to develop tolerizing therapies for multiple autoimmune diseases. The collaboration aims to develop treatments that restore immune homeostasis and provide patients with durable remission of their disease without the generalized immune suppression that is common with currently available therapies. Repertoire will lead collaboration activities until development candidate nomination, and Lilly will lead clinical development, manufacturing, regulatory affairs and commercialization of tolerizing therapies developed under the collaboration.
Under the terms of the agreement, Repertoire will receive an upfront payment of $85 million and up to an additional $1.84 billion for achieving certain development and commercial milestones, as well as tiered royalties on net sales.
Repertoire Immune Medicines is discovering the unique immune codes that determine how we maintain health and respond to disease. Repertoire’s proprietary DECODE™ platform uniquely elucidates the entire immune synapse, providing a comprehensive understanding of the interactions between T cell receptors and their cognate antigenic epitopes. Repertoire is translating these insights into new and potentially transformative T cell-targeted therapies for the treatment of cancer and autoimmune diseases via a wholly owned pipeline and via partnerships with Bristol Myers Squibb, Genentech, Pfizer and Eli Lilly and Company. Repertoire was founded in 2019 by Flagship Pioneering. Its team operates from sites in Cambridge, Massachusetts and Zurich.
The Goodwin team was led by Shane Albright and Kingsley Taft, and included Stephanie Richards, Minji Kim and Carrie Clowney.
For more information on the deal, please read the press release.